eligibility_summary
Inclusion: Adults 18–80 with primary cervical SCC (FIGO IB3–IVA), measurable disease (RECIST 1.1), ECOG 0–1, adequate organ function, WOCBP negative test/contraception, consent. Exclusions: non‑SCC, prior therapy, pregnancy/lactation, fistula, unmanageable ureteral obstruction, recent major surgery/live vaccine, HIV/active HBV/HCV, serious CV/infectious/metabolic disease, autoimmune/immunosuppressed, other malignancy/IBD, drug allergy/contraindication, not brachytherapy‑eligible.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Nimotuzumab (humanized anti-EGFR IgG1 monoclonal antibody, biological) added to standard chemoradiotherapy (weekly cisplatin, a platinum DNA–crosslinking cytotoxic/radiosensitizer, plus EBRT then brachytherapy), followed by nimotuzumab maintenance, control uses placebo with the same chemoradiotherapy. If incomplete response, optional adjuvant cisplatin or carboplatin (platinum cytotoxics) plus paclitaxel (taxane microtubule inhibitor). Mechanisms/targets: Nimotuzumab binds EGFR on tumor cells, blocking ligand activation, receptor signaling (RAS–RAF–MEK–ERK, PI3K–AKT), reducing proliferation/survival and potentially mediating ADCC and radiosensitization. Cisplatin/carboplatin and radiation induce DNA damage (crosslinks, double-strand breaks), exploiting DNA damage response pathways. Paclitaxel stabilizes microtubules, arresting mitosis. Targets: EGFR-expressing cervical squamous carcinoma cells, DNA repair pathways, microtubule dynamics.